fH1 2 ug + fH1 8 ug + DSP-0546LP 2.5 ug + DSP-0546LP 5 ug + DSP-0546LP 10 ug + Placebo

Phase 1Active

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Influenza

Conditions

Influenza

Trial Timeline

Jun 26, 2024 → Mar 27, 2026

NCT ID

NCT06460064

About fH1 2 ug + fH1 8 ug + DSP-0546LP 2.5 ug + DSP-0546LP 5 ug + DSP-0546LP 10 ug + Placebo

fH1 2 ug + fH1 8 ug + DSP-0546LP 2.5 ug + DSP-0546LP 5 ug + DSP-0546LP 10 ug + Placebo is a phase 1 stage product being developed by Sumitomo Pharma for Influenza. The current trial status is active. This product is registered under clinical trial identifier NCT06460064. Target conditions include Influenza.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06460064	Phase 1	Active	Jun 26, 2024	Mar 27, 2026	Influenza

Competing Products

20 competing products in Influenza

See all competitors

Product	Company	Stage	Hype Score
Influenza vaccine, split inactivated	Comac Medical	Phase 1	25
Vaccine	Comac Medical	Phase 3	69
CT-P27 90 mg/kg + CT-P27 45 mg/kg + Placebo	Celltrion	Phase 2	52
CT-P27 + Placebo	Celltrion	Phase 2	52
CAIV-T	Pfizer	Phase 3	76
CS-8958 + CS-8958 + oseltamivir phosphate	Daiichi Sankyo	Phase 3	77
Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to Oseltamivir	Shionogi	Phase 3	77
Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to Oseltamivir	Shionogi	Phase 3	77
Monovalent Influenza Vaccine	AstraZeneca	Approved	85
Monovalent Influenza Vaccine	AstraZeneca	Approved	85
Trivalent Influenza Vaccine	AstraZeneca	Approved	85
AZD4117 + AZD5315	AstraZeneca	Phase 1/2	41
Trivalent Influenza Vaccine	AstraZeneca	Approved	85
FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018)	AstraZeneca	Approved	85
Trivalent Influenza Virus Vaccine	AstraZeneca	Approved	85
Comparator: Modified Process Vaccine + Comparator: COMVAX™	Merck	Phase 3	77
Molnupiravir + Placebo molnupiravir + Placebo oseltamivir + Oseltamivir + Influenza A Virus	Merck	Phase 1	33
V512 + Comparator: Placebo to V512	Merck	Phase 1	33
Vaxelis + PedvaxHIB	Merck	Approved	85
Seasonal Influenza Vaccine	Novartis	Phase 2	52

Other Products from Sumitomo Pharma

BlonanserinApproved

Mosapride + domperidoneApproved

levalbuterol HCl + albuterol SulfateApproved

LurasidoneApproved

placebo, isotonic ciclesonide, hypotonic ciclesonideApproved